

BS = Bariatric surgery

Figure S1. Flowchart for participants in the BARIHTA Study. * Most patients rejected to complete the study because of complains about wearing the 24h-Mobile-O-Graph® device or due to work reasons (having achieved work reinsertion after losing weight)




Figure S2. Body weight change at follow-up.

Table S1. Changes in adipokines and inflammatory markers 12-months after bariatric surgery.

| | Before BS | 12- months post-BS | p |
|----------------------------------|-------------------------------|-------------------------------|------------------|
| Leptin* , ng/mL | 56.5 [28.8; 73.7] | 12.8 [8.1; 33.2] | <0.001 |
| Adiponectine* , µg/mL | 19.0 [12.5; 33.3] | 29.0 [15.5; 59.0] | 0.017 |
| Resistin , ng/mL | 37.4 ± 15.9 | 33.6 ± 12.1 | 0.091 |
| MCP-1 , pg/mL | 556.6 ± 204.1 | 554.0 ± 219.8 | 0.930 |
| Angiopoietin2* , µg/mL | 2676.2 [1815.4; 4067.0] | 4540.5 [2094.2; 6190.4] | 0.012 |
| hs-CRP* , mg/dL | 0.77 [0.43; 1.41] | 0.11 [0.06; 0.29] | <0.001 |

(*) Data shown as median [interquartile range]

BS = bariatric surgery; **hs-CRP** = C-reactive protein; **MCP-1** = monocyte chemoattractant protein-1

Table S2. Determinants of variation of eGFR (S2A) and of variation of albuminuria (S2B)

S2A.

| eGFR | All patients (n = 62) | | | Patients without antihypertensive treatment (n = 42) | | |
|-----------------------|-----------------------|--------------|------------------|--|--------------|--------------|
| | Coeff. | 95% CI | p-value | Coeff. | 95% CI | p-value |
| Months FU | -0.56 | -1.98, 0.87 | 0.443 | -0.95 | -2.88, 0.99 | 0.337 |
| Body weight, Kg | 0.66 | 0.35, 0.96 | <0.001 | 0.50 | 0.11, 0.88 | 0.012 |
| 24h-systolic BP, mmHg | 0.32 | -0.04, 0.67 | 0.082 | -0.04 | -0.54, 0.46 | 0.872 |
| Aldosterone, ng/dL | -0.10 | -0.15, -0.05 | <0.001 | -0.06 | -0.12, -0.00 | 0.033 |
| HOMA index | 0.47 | -0.62, 1.57 | 0.398 | 1.25 | 0.13, 2.37 | 0.029 |

BP = blood pressure; eGFR = estimated glomerular filtration rate; FU = follow-up; HOMA = homeostasis model assessment-estimated insulin resistance.

S2B.

| lnACR | All patients (n = 62) | | | Patients without antihypertensive treatment (n = 42) | | |
|-----------------------|-----------------------|--------------|------------------|--|-------------|--------------|
| | Coeff. | 95% CI | p-value | Coeff. | 95% CI | p-value |
| Months FU | -0.02 | -0.07, 0.02 | 0.278 | -0.04 | -0.10, 0.01 | 0.119 |
| Body weight, Kg | -0.00 | -0.01, 0.00 | 0.364 | -0.00 | -0.01, 0.01 | 0.516 |
| 24h-systolic BP, mmHg | 0.02 | 0.01, 0.03 | <0.001 | -0.01 | -0.02, 0.01 | 0.333 |
| Aldosterone, ng/dL | 0.00 | --0.00, 0.00 | 0.430 | 0.00 | -0.00, 0.00 | 0.980 |
| HOMA index | 0.05 | 0.01, 0.08 | 0.012 | 0.04 | 0.01, 0.07 | 0.022 |

BP = blood pressure; FU = follow-up; HOMA = homeostasis model assessment-estimated insulin resistance; lnACR = log-transformed albumin-creatinine ratio.